Clinical development failure
Early-stage CNS programs can fail on efficacy, safety or tolerability before commercialization.
- Scope
- GT-002 and future pipeline assets
- Materiality
- high
Gabather
Gabather is a Swedish clinical-stage biopharmaceutical company focused on developing selective GABAA receptor stimulators for psychiatric and neuropsychiatric disorders. Its lead candidate, GT-002, is being advanced for conditions linked to imbalance in the GABA system, including depression, schizophrenia, psychosis, Alzheimer’s disease and autism.
| % | |
|---|---|
| Lead clinical candidate GT-002 | 60% The company's most advanced drug candidate being developed for psychiatric indications. |
| Selective GABAA receptor stimulators | 25% A platform of compounds designed to modulate the GABA system for CNS disorders. |
| Drug discovery pipeline | 15% Programs to identify and advance new candidates for future clinical development. |
Gabather does not sell commercial medicines today; its direct counterparties are typically development partners,...
- Pharmaceutical licensing partnersprimary
Large drug companies that may license GT-002 or related assets after clinical data de-risks the program.
- Research and development collaboratorssecondary
Academic or industry partners that support discovery, translational work and clinical studies.
- Future patient populationsemerging
Patients with depression, schizophrenia, psychosis, Alzheimer’s disease or autism who would use approved therapies.
Gabather is headquartered in Sweden and listed on Nasdaq First North Growth Market. Its business is globally oriented...
- •Headquartered and listed in Sweden
- •Clinical and regulatory work is tied to Swedish operations
- •Future partnering would likely be international
- •Target diseases have global patient populations
Gabather’s strategy is to advance GT-002 through early clinical studies in-house until meaningful efficacy data are...
01
Generate early clinical efficacy data for GT-002short-term
Proof-of-concept is the key value inflection point for partnering and valuation.
02
Secure a development and commercialization partnermedium-term
A larger partner can fund late-stage trials and market access.
03
Broaden the pipeline of GABAA-based candidatesmedium-term
A broader portfolio can reduce single-asset dependence and improve partnering optionality.
Gabather is exposed to the typical risks of early-stage drug development: clinical failure, regulatory setbacks, patent...
Patent and IP protection
The business depends on protecting novel mechanisms and candidate-specific rights.
- Scope
- Selective GABAA stimulators and GT-002
- Materiality
- high
Regulatory risk
Drug development requires favorable decisions from health authorities at each stage.
- Scope
- Clinical trials and future approvals
- Materiality
- high
Financing risk
As a development-stage company, Gabather must fund research before any product revenue exists.
- Scope
- Corporate operations and clinical programs
- Materiality
- high
Partnering dependence
The intended business model relies on securing a larger partner after early data.
- Scope
- Commercialization pathway for GT-002
- Materiality
- high
Research and development expense recognition
Affects operating loss and comparability across periods
Share-based compensation
Affects personnel expense and diluted share count
Deferred tax assets on tax losses
Can materially affect balance sheet tax assets
Impairment and valuation judgments
Could lead to write-downs if project prospects weaken
: 11/08/2026